



COVID-19 Vaccine Comparison Chart

Vaccine Name	Comirnaty	SpikeVax	Johnson & Johnson	NVX-CoV2373	Vaxzevria	Sputnik V	CVnCoV	BBiP-CorV	CoronaVac	
Manufacturer	Pfizer-BioNTech	Moderna	Janssen Pharmaceutica	Novavax	Oxford-AstraZeneca	Gamaleya	CureVac N.V. & CEPI	Sinopharm	Sinovac Biotech	
MOA	mRNA vaccine	mRNA vaccine	Adenovirus vector vaccine	Protein-based vaccine	Adenovirus vector vaccine	Adenovirus vector vaccine	mRNA vaccine	Inactivated coronavirus	Inactivated coronavirus	
Dosing Schedule	2 doses, 21 days apart	2 doses, 28 days apart	1 dose	2 doses, one month apart	2 doses, three months apart	Sputnik Light requires one dose.	2 doses, four weeks apart	2 doses, three weeks apart	2 doses, two to four weeks apart	
Efficacy	95% at least 7 days after dose 2	94.1% at least 14 days after dose 2	72% in the U.S. and 66% globally against moderate-to-severe disease; 85% effective against severe disease, 28 days after a single dose.	Vaccine demonstrated 100% protection against moderate and severe disease, 90.4% efficacy overall, and met the primary endpoint in its PREVENT-19 pivotal Phase 3 trial.	76% in a U.S. study against symptomatic COVID-19; 100% effective severe disease; 85% efficacy against symptomatic COVID-19 in those 65+	In a press release, the Gamaleya National Center of Epidemiology and Microbiology in Moscow claimed a large-scale Russian study saw 92% efficacy for its vaccine. However, other scientists have voiced concerns this claim is based on too few cases. Although the vaccine was trialled on 18,000 people, the efficacy claim has been based on an analysis of only 39 individuals to test positive with coronavirus. September 12, 2021 update: Research published in <i>The Lancet</i> states that Sputnik V demonstrated 78.6-83.7% real-world efficacy amongst 40,000 elderly people in Argentina.	Publication of efficacy results have been delayed from May 2021, according to a CureVac press release on May 28, 2021.	78% according to the World Health Organization	Approximately 50% according to Sinovac's Phase 3 trial. However, real-world effectiveness has been shown to be approximately 67%.	
	July 28, 2021 update: Pfizer reports that their vaccine efficacy wanes to 84% after six months post-vaccination.	August 5, 2021 update: Moderna releases statement sharing their vaccine has a 93% efficacy rate through six months after the second dose.	June 30, 2021 update: Results from the Phase 3 trial in the UK indicate an overall vaccine efficacy rate of 89.7%.	June 2021 update: The Russian Direct Investment Fund announces that Sputnik Light demonstrated 78.6-83.7% efficacy amongst the elderly population in Argentina.	June 16, 2021 update: Preliminary analysis of CureVac's Phase 3 trial showed a 47% efficacy rate. Researchers have since noted that the vaccine dosage may have been a factor leading to low efficacy; CureVac still plans to apply for EUA.					
Authorization	U.S. EUA	Dec 11, 2020	Dec 18, 2020	Feb 27, 2021	<i>Expected to file for regulatory approval in third quarter</i>					
	U.S. FDA	Approved Aug 23, 2021 for ages 16+	<i>submitted for approval</i>							
	U.K. EUA	Dec 2, 2020	Jan 8, 2021	May 28, 2021	<i>Expected to file for approval September 2021</i>	Dec 30, 2020				
	E.U. EUA	Dec 21, 2020	Jan 6, 2021	Mar 11, 2021	<i>Expected to submit data by October 2021</i>	Jan 29, 2021				
	Russia						Nov 2020			
	Canada		September 16, 2021 update: Approved by Health Canada for those 12+							
	W.H.O.						<i>Suspended as of Sept 16, 2021 due to manufacturing concerns</i>	May 7, 2021	June 1, 2021	
	Boosters	Germany, Israel, UAE, France, Hungary, Turkey, Thailand, UK, Czech Republic, Austria, Belgium, Lithuania, Brazil, Singapore, USA	Germany, Hungary, Czech Republic, Austria, Belgium, France, UK, Singapore	Hungary		Hungary, Chile, Thailand	Russia		Hungary, UAE, China	Turkey, China
		August 12, 2021: FDA authorizes additional doses for the immunocompromised. August 18, 2021: FDA announces they will likely offer booster shots for all Americans beginning the week of September 20 and starting 8 months after an individual's second dose. September 22, 2021 update: FDA amends EUA to allow for booster dose in those 65+, those 18+ at high risk for severe COVID-19, and those 18+ with high risk of exposure due to their occupation, which puts them at high risk of serious COVID-19. The booster EUA only applies to the Pfizer vaccine.	August 13, 2021: FDA authorizes additional doses for the immunocompromised. August 18, 2021: FDA announces they will likely offer booster shots for all Americans beginning the week of September 20 and starting 8 months after an individual's second dose. September 1, 2021: Moderna submits initial data for booster to FDA. September 13, 2021: Moderna submits data for booster to EMA.	August 18, 2021: FDA anticipates booster shots "will likely be needed for people who received the J&J vaccine. Administration of the J&J vaccine did not begin in the U.S. until March 2021, and we expect more data on J&J in the next few weeks. With those data in hand, we will keep the public informed with a timely plan for J&J booster shots as well."						
	Age	Authorized for ages 12+ by the FDA, European Medicines Agency (EMA) and the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK.	Authorized for ages 18+ in US, pending for ages 12-17. Authorized for ages 12+ by MHRA in UK.	Authorized for ages 18+.		Authorized for ages 18+, with age limitations in EU certain countries.	Approved for ages 18+.		Granted EUA by the WHO for ages 18+.	Granted EUA by the WHO for ages 18+.
		July 23, 2021: The EMA authorized the use of the Moderna vaccine in children 12+. August 17, 2021: MHRA authorizes use in 12- to 17-year-olds in the UK.						July 20, 2021: Authorized in China for ages 3+ August 2, 2021: Approved in UAE for ages 3+	June 5, 2021: Authorized in China for ages 3+ September 6, 2021: Authorized in Chile for ages 6+	



COVID-19 Vaccine Comparison Chart

Vaccine Name	Comirnaty	SpikeVax	Johnson & Johnson	NVX-CoV2373	Vaxzevria	Sputnik V	CVnCoV	BBiP-CoV	CoronaVac	
Manufacturer	Pfizer-BioNTech	Moderna	Janssen Pharmaceutica	Novavax	Oxford-AstraZeneca	Gamaleya	CureVac N.V. & CEPI	Sinopharm	Sinovac Biotech	
R e s e a r c h a n d D e v e l o p m e n t H i g h l i g h t	Q1 2020	3/16/2020: Moderna begins Phase 1 human clinical trial for their mRNA COVID-19 vaccine in the U.S.							January 2020: Sinovac begins developing a vaccine using an inactivated coronavirus strain.	
	Q2 2020	4/29/2020: Human trials begin in Germany.	5/12/2020: Moderna receives Fast Track designation from the FDA to proceed with a Phase 2 study of their vaccine.					4/29/2020: Researchers begin Phase 1 trial.		
		5/5/2020: Pfizer and BioNTech Dose 1st U.S. Participants.	5/18/2020: Moderna releases interim data from their Phase 1 clinical trial, stating plans for a Phase 3 trial to begin in July.		5/1/2020: Novavax announces a combined Phase 1/2 clinical trial, with phase 1 starting in Australia and Phase 2 to be conducted in multiple countries following the results of Phase 1.			May 2020: CureVac announces positive results for vaccine candidate in preclinical experiments.		
			5/29/2020: Moderna announces purpose and enrollment of Phase 2 clinical trial. Enrollment was completed July 8.				June 2020: The Gamaleya Research Institute begins clinical trials for a combination adenovirus vaccine.		6/6/2020: Researchers confirm promising results from trial in monkeys, stating the vaccine is genetically stable and seems to be safe in animals.	
	Q3 2020		7/14/2020: Moderna publishes interim results of their Phase 1 trial in <i>The New England Journal of Medicine</i> .	7/30/2020: Single dose of J&J vaccine candidate demonstrates robust protection in pre-clinical studies.	8/4/2020: Novavax announces the results of Phase 1 of the Phase 1/2 clinical trial stating the vaccine was "generally well-tolerated and elicited robust antibody responses."	7/20/2020: AstraZeneca's Phase 1 human clinical trial results are published in <i>The Lancet</i> ; results show vaccine is safe and create an immune response.			July 2020: China launches vaccine program to distribute Sinovac, Sinopharm and CanSino Covid-19 vaccines within China. Phase 3 testing was not complete at the time. Additional trials launched in Brazil, Indonesia, and Turkey.	
			7/27/2020: Moderna begins Phase 3 clinical trial, enrolling 30,000 adults across the U.S.	9/3/2020: Vaccine prevents severe disease in pre-clinical studies.	8/24/2020: Novavax announces the initiation of Phase 2 of its Phase 1/2 clinical trials. Participants are enrolled in both the U.S. and Australia.					
		8/12/2020: Peer-Reviewed Phase 1/2 Data Published in <i>Nature Magazine</i> .		9/23/2020: Global Phase 3 'Ensemble' Clinical Trials begin.	9/2/2020: Novavax announces publication of Phase 1 results in <i>The New England Journal of Medicine</i> .					8/10/2020: Results of a Phase 1/2 trial are published stating no safety concerns were observed amongst 743 volunteers. Adverse events were mild in severity, and primarily isolated to pain at the injection site. The results have not been peer reviewed.
				9/25/2020: Interim results from Phase 1/2a clinical trial support further clinical development of vaccine, but Phase 3 PAUSED after a serious medical event experienced by 1 study participant.	9/24/2020: Novavax announces initiation of Phase 3 clinical trial using 10,000 participants across the U.K. (enrollment is completed 11/30/2020).	9/1/2020: Phase 3 clinical trials begin in the U.S.	9/4/2020: The Gamaleya Research Institute publishes the results of their Phase 1/2 clinical trial, announcing their Sputnik V vaccine yielded antibodies with only mild side effects.			
	Q4 2020		11/16/2020: Moderna releases preliminary data from Phase 3 clinical trial, stating their vaccine is 94.5% effective. The data is released in full on November 30.	10/23/2020: Phase 3 Ensemble Trial resumes.			10/17/2020: Phase 2/3 trial launches in India.		10/17/2020: Research published in <i>The Lancet</i> shares the results of a Phase 1/2 trial, showing the vaccine stimulates the production of antibodies and does not cause serious adverse effects.	10/19/2020: Officials in Brazil quote Sinovac's vaccine as being the safest of five being tested in Phase 3 trials.
		11/18/2020: Pfizer and BioNTech conclude Phase 3 Study, meeting all primary and secondary efficacy endpoints.	12/2/2020: Moderna files to test their vaccine in adolescents 12-18 years of age. Moderna announces clinical trial on March 10, 2021.	11/16/2020: Announcement of second Phase 3 clinical trial to observe the use of two doses versus one.		11/23/2020: AstraZeneca and the University of Oxford announce the initial results of the Phase 3 clinical trials in the U.K., Brazil, and South Africa. The study showed the vaccine was safe and effective. Data from the study was published 11/19 in <i>The Lancet</i> .	11/11/2020: The Russian Direct Investment Fund announces that Sputnik's Phase 3 clinical trial demonstrated high efficacy rates, determining a 92% efficacy rate for the Sputnik V vaccine.	November 2020: CureVac reports positive interim Phase 1 data for its COVID-19 vaccine candidate.	November 2020: Sinopharm reports that over 1 million doses have been administered to the public.	11/17/2020: Sinovac publishes the results of their Phase 1/2 trial in <i>The Lancet</i> .
		12/10/2020: Pfizer and BioNTech Announce Publication of Results from Phase 3 Trial in <i>The New England Journal of Medicine</i> .	12/31/2020: Moderna publishes results of Phase 3 trial in <i>The New England Journal of Medicine</i> .		12/28/2020: Novavax announces initiation of Phase 3 efficacy trial in U.S. and Mexico.		December 2020: The Gamaleya Research Institute and AstraZeneca decide to combine vaccines in an effort to increase the efficacy of the AstraZeneca vaccine, with clinical trials beginning in February 2021.	12/23/2020: CureVac begins Phase 3 trial using 36,500 participants across Europe and Latin America. Results are presumed to be released in May 2021.	12/30/2020: Sinopharm states their vaccine has an efficacy rate of 79%.	12/23/2020: Brazil announces that CoronaVac has an efficacy rate of over 50%. 12/24/2020: Turkey announces that the vaccine has an efficacy rate of over 91%.
				1/13/2021: Interim Phase 1/2a Data published in <i>New England Journal of Medicine</i> .	1/13/2021: Interim Phase 1/2a Data published in <i>New England Journal of Medicine</i> .	2/3/2021: Oxford and AstraZeneca publish more data from clinical trials regarding efficacy and prevention.				1/7/2021: Researchers in Brazil specify that the CoronaVac vaccine has an efficacy rate of 78% and prevents severe disease. This figure was based on the results of a volunteer subgroup; the efficacy rate was not officially released.
Q1 2021		3/5/2021: Moderna announces Phase 1 clinical trial testing their vaccine against the B.1.351 variant.	1/29/2021: Johnson & Johnson announce that their Phase 3 trial show their vaccine to be safe and effective; the results of the trial are published in <i>The New England Journal of Medicine</i> April 29, 2021.	January 2021: Novavax announces that vaccine demonstrated 96% efficacy in a 15,000 person trial in Britain.	2/15/2021: Oxford University begins a clinical trial testing the vaccine in children.				1/13/2021: Brazilian researchers backtrack and announce that the CoronaVac actually has an efficacy rating of just over 50%.	
	2/25/21: Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants.	3/15/2021: Moderna announces Phase 1 trial of refrigerated-stable vaccine.	2/21/2021: Johnson & Johnson announce upcoming clinical trial with pregnant women.			2/2/2021: The Gamaleya Research Institute, in part with Russia's Ministry of Health, publishes the results of their Phase 3 trial in <i>The Lancet</i> .	2/12/2021: The European Union begins a "rolling review" process of the Phase 3 trial, in order to speed the authorization process once the trial is completed and results are announced.			



COVID-19 Vaccine Comparison Chart

Vaccine Name	Comirnaty	SpikeVax	Johnson & Johnson	NVX-CoV2373	Vaxzevria	Sputnik V	CVnCoV	BBiP-CorV	CoronaVac
Manufacturer	Pfizer-BioNTech	Moderna	Janssen Pharmaceutica	Novavax	Oxford-AstraZeneca	Gamaleya	CureVac N.V. & CEPI	Sinopharm	Sinovac Biotech
S			3/5/2021: Vaccine Granted Authorization under Interim Order by FDA For Emergency Use.						2/6/2021: Sinovac receives conditional approval for the CoronaVac vaccine in China. The approval was based on two months of clinical data. Final efficacy and safety results from Phase 3 trials have not been confirmed.
			3/11/2021: Vaccine Candidate Receives Positive CHMP Opinion and Granted Conditional Marketing Authorization by European Commission.		3/22/2021: AstraZeneca announces interim results from clinical trial in the U.S. and South America.				
	3/31/2021: Pfizer announces positive topline results of their clinical trial in adolescents ages 12-15, in which the vaccine demonstrated 100% efficacy and produced a robust antibody response. The vaccine was also well tolerated.	3/16/2021: Phase 2/3 study in pediatric/adolescents begins.	3/12/2021: Granted Emergency Use Listing by the World Health Organization.		3/25/2021: AstraZeneca announces beginning of Phase 1 trial investigating use of vaccine components in a nasal spray.	3/29/2021: Russia announces that "Sputnik Light" will be registered for use after the clinical trial, which began in January. This single-dose version of the Sputnik vaccine is proposed to provide 4-5 months of protection against the novel coronavirus.			
Q2 2021	5/5/2021: Researchers at Pfizer and Israel's Ministry of Health observe Pfizer vaccine to be over 95% effective against infection, hospitalization and death against the B.1.1.7 variant amongst Israel's vaccinated population. The results of the study are shared in The Lancet.	5/6/21: Moderna announces that vaccine is 96% effective in preventing infection in children 12+.	4/2/2021: Expands Phase 2a Clinical Trial to Include Adolescents.	5/3/2021: Novavax expands Phase 3 trial to include children ages 12+.				4/28/2021: A third vaccine enters Phase 1/2 clinical trials.	April 2021: Sinovac releases the results of a Phase 3 trial showing that their vaccine is around 50% effective in preventing COVID-19 infections. Observing real-world results in Chile found it to be 67% effective in preventing infection.
	5/25/21: Pfizer begins Phase 3 trial using their pneumococcal vaccine candidate in conjunction with the Pfizer Covid-19 vaccine as a booster in adults 65+.	5/28/2021: Moderna begins Phase 1/2 clinical trial on the use of the Moderna vaccine as a booster shot to a range of other vaccine brands.		5/21/2021: Novavax announces its participation in a UK mix-and-match booster trial alongside 6 other vaccine manufacturers. The study will include participants who have previously been vaccinated with 2 doses of an authorized vaccine.		5/6/2021: The Russian government authorizes Sputnik Light for use after their Ministry of Health announces Sputnik Light is 79.4% effective. Details of the study are not released.	5/28/2021: CureVac releases statement verifying that an independent Data Safety Monitoring Board found the vaccine to be safe; they are waiting to release further information regarding the trial, to include efficacy data, by the end of June.	5/7/2021: The World Health Organization states that Sinopharm's vaccine has an efficacy rate of 78%, and authorizes it for emergency use. The results of the Phase 3 trial have not yet been released.	5/13/2021: Sinovac begins Phase 2 clinical trial on children 3-17 years old.
								5/23/2021: UAE announces they will distribute a third booster shot of the vaccine.	
	6/8/2021: Pfizer announces advancement of Phase 2/3 clinical trials in children ages 5-11.	6/15/2021: Moderna begins clinical trial testing their vaccine as a booster shot.		6/14/2021: Novavax releases the results of their Phase 3 clinical trial in the US and Mexico, stating their vaccine is 90.4% effective overall, with 100% efficacy against moderate and severe disease.	6/27/2021: AstraZeneca starts Phase 2/3 clinical trial on vaccine specially tailored against the beta variant.			6/3/2021: Bahrain announces a third booster shot.	
	6/28/2021: A study published in Nature confirms the Pfizer vaccine is highly effective against variants, including delta.	6/29/2021: Moderna announces that a full dose of their vaccine provides protection against the delta, zeta and kappa variants.		6/30/2021: Novavax publishes the results of their Phase 3 trial in the New England Journal of Medicine. The trial was conducted in the UK and showed an overall vaccine efficacy rate of 89.7%. The vaccine showed 96.4% efficacy against non-B.1.1.7 variants, which parallel strains of the original virus.	6/28/2021: Oxford researchers confirm that a third dose of the AstraZeneca vaccine elicited a strong immune response in clinical trial participants. Clinical trial data is still being peer-reviewed.	6/2/2021: The Russian Direct Investment Fund announces that Sputnik Light demonstrated 78.6-83.7% efficacy amongst the elderly population in Argentina.	6/16/2021: Following the Phase 2b/3 study (40,000 subjects), CVnCoV demonstrated an interim vaccine efficacy of 47% against COVID-19 disease of any severity and did not meet prespecified statistical success criteria.	6/10/2021: UAE begins testing in children ages 3-17.	6/19/2021: Sinovac begins Phase 4 clinical trial testing the efficacy of a booster shot. Participants include those 18-59 years of age. 6/28/2021: Sinovac publishes the results of a Phase 1/2 clinical trial testing their Covid-19 vaccine in youths ages 3-17. The study demonstrated high immunogenicity and safety levels.
Q3 2021	7/8/2021: Pfizer announces the development of a new coronavirus vaccine that specifically targets the Delta variant; clinical trials are expected to begin next month.		7/1/2021: Regarding the delta variant, J&J stated the vaccine offers effective protection. They have submitted a pre-print of data from the laboratory study to bioRxiv, further citing that immunity from the vaccine lasts at least 8 months.		7/21/2021: A study published in the New England Journal of Medicine shows that two doses of the AstraZeneca vaccine are 67% effective in neutralizing the Delta variant.	7/12/2021: A study on behalf of the Ministry of Health of the Russian Federation shows that antibodies from the Sputnik V vaccine effectively neutralize the Delta variant, albeit less than previous strains.		7/19/2021: Sinopharm publishes results of study coming out of Sri Lanka, showing their vaccine was effective in neutralizing the Delta variant. The results have not been peer-reviewed.	7/25/2021: Coronavac publishes interim results of Phase 2 clinical trial using booster shots 6-8 months after second dose. Boosters resulted in a "remarkable increase in antibody levels."



COVID-19 Vaccine Comparison Chart

Vaccine Name	Comirnaty	SpikeVax	Johnson & Johnson	NVX-CoV2373	Vaxzevria	Sputnik V	CVnCoV	BBiP-CorV	CoronaVac
Manufacturer	Pfizer-BioNTech	Moderna	Janssen Pharmaceutica	Novavax	Oxford-AstraZeneca	Gamaleya	CureVac N.V. & CEPI	Sinopharm	Sinovac Biotech
	<p>7/27/2021: Pfizer begins recruiting for clinical trial testing a second dose in those who experienced a systemic allergic reaction to the first dose of the Pfizer or Moderna vaccine.</p> <p>7/28/2021: Pfizer releases statement suggesting need for boosters, citing study that shows their vaccine's efficacy wanes to 83.7% by six months after the second dose. The study's results not been peer-reviewed.</p> <p>8/25/2021: Pfizer releases data showing antibodies more than tripled in participants who received a booster dose 5-8 months after being fully vaccinated. Details of the study have not been released yet.</p>	<p>8/5/2021: Moderna releases statement suggesting the need for boosters after 6 months, especially in light of the Delta variant. Clinical trial results cite a 93% efficacy rate through 6 months after the second dose, and a 98.3% efficacy rate against severe disease. Moderna is currently holding a clinical trial using a half dose of the vaccine; interim results show an uptick of antibodies that effectively neutralize the Delta variant.</p>	<p>8/25/2021: Johnson & Johnson announces that boosters raised antibody levels by 9x after the initial dose. These results follow a small trial including 17 participants, 6 months after their initial dose. The data has not been published yet.</p>	<p>8/5/2021: Novavax issues statement on results from ongoing Phase 2 study, showing their vaccine demonstrated 4x increase in antibodies when used as a booster and 6x increase in antibodies against Delta variant compared to antibody response after primary vaccination series. Results have not been peer-reviewed.</p>		<p>8/11/2021: Researchers announce that pre-clinical trials of an intranasal version of the Sputnik V vaccine have been completed. The research has not been released.</p>		<p>8/2/2021: UAE announces they will start providing vaccines to children ages 3-17.</p> <p>8/3/2021: A Hungarian study shows that the vaccine failed to produce sufficient antibodies in a tier of elderly participants.</p> <p>8/13/2021: A clinical trial coming out of Peru indicates the vaccine is 50.4% effective in preventing infection.</p>	<p>8/5/2021: Sinovac starts Phase 3 trial using vaccine in participants 6 months through 17 years of age.</p> <p>8/4/2021: Sinovac starts recruiting for Phase 4 trial on booster shots in healthy adults ages 18-59.</p>
	<p>9/20/2021: Pfizer announces that in participants 5 to 11 years of age, the vaccine was safe, well tolerated and showed robust neutralizing antibody responses</p>	<p>9/9/2021: Moderna announces the development of a vaccine that combines a COVID-19 booster dose with an experimental flu shot.</p> <p>9/15/2021: Moderna publishes pre-print study on <i>medRxiv</i> stating that people vaccinated within the past 6 months have experienced 36% fewer breakthrough cases than those vaccinated a year ago.</p>	<p>9/21/2021: Johnson & Johnson announces real-world and Phase 3 efficacy data confirming long-lasting protection from single dose of vaccine. They also presented data showing booster offers 94% protection against moderate to severe COVID-19 when administered at 2 months after primary vaccination.</p>	<p>9/8/2021: Novavax announces early-stage study combining flu and COVID-19 vaccine.</p>		<p>9/15/2021: The Russian Direct Investment Fund announces that the Sputnik V vaccine demonstrated 97.2% in Belarus' vaccination campaign.</p> <p>9/15/2021: Sputnik Light gets go-ahead for Phase 3 trial in India.</p>		<p>9/6/2021: Announcement of development of mRNA COVID-19 vaccine. 9/17/2021: A study published in <i>The Lancet</i> showed that the Sinopharm vaccine was deemed safe in participants 3-18 years of age.</p>	<p>9/6/2021: Chinese media reports announce that a third dose of Sinovac prolongs immunity against SARS-CoV-2. The lab study cited has not been peer-reviewed</p>
Reported Adverse Reactions*	<ul style="list-style-type: none"> - Myocarditis and pericarditis - Immune thrombocytopenia - Bell's Palsy 	<ul style="list-style-type: none"> - Immune thrombocytopenia - Bell's Palsy 	<ul style="list-style-type: none"> - Guillain-Barre syndrome - Thrombosis with thrombocytopenia syndrome 		<ul style="list-style-type: none"> - Thrombosis with thrombocytopenia syndrome 				

* The adverse events included in this list have been verified by the CDC, FDA and/ or WHO. Official statements regarding these adverse events can be found on the respective websites.